GlassScriptPhysician profile
Michael Raymond Butzen
NPI 1760036776
$6,546.74
in general payments reported to CMS, 2019-2025
30 companies · $865 in 2025
The $865 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $1,439 · 2023: $2,283 · 2024: $991 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.36 |
| Education | $307.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $1,099.71 | 2021-2025 | Kimyrsa, Orbactiv, Vabomere |
| Viiv Healthcare Company | $827.98 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Paratek Pharmaceuticals, INC. | $765.04 | 2021-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $567.23 | 2021-2025 | Delstrigo, Pifeltro, Dificid |
| Astellas Pharma US INC | $488.30 | 2021-2025 | Cresemba, Xtandi |
| Gilead Sciences, INC. | $457.47 | 2021-2025 | Epclusa |
| Abbvie INC. | $408.12 | 2021-2025 | |
| Janssen Biotech, INC. | $302.72 | 2021-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $243.62 | 2021-2024 | Xerava |
| Cumberland Pharmaceuticals, INC. | $236.46 | 2022-2025 | Vibativ |
| Insmed, INC. | $148.61 | 2021-2025 | Arikayce |
| Shionogi INC | $131.74 | 2022-2023 | Fetroja |
| Janssen Products, LP | $130.49 | 2021 | |
| Ferring Pharmaceuticals INC. | $107.19 | 2022-2024 | Rebyota |
| Octapharma USA, INC. | $102.89 | 2022-2023 | Panzyga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $81.31 | 2023-2025 | Xembify |
| Boston Scientific Corporation | $73.29 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $63.04 | 2025 | Gemtesa |
| Theratechnologies INC. | $51.67 | 2023-2025 | Trogarzo, Egrifta |
| Takeda Pharmaceuticals U.S.A., INC. | $43.10 | 2023 | Cuvitru |
| Progenics Pharmaceuticals, INC. | $27.77 | 2025 | |
| Urogen Pharma, INC. | $27.53 | 2025 | |
| Aimmune Therapeutics, INC. | $26.91 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $23.62 | 2025 | |
| Pfizer INC. | $23.50 | 2024 | |
| Angiodynamics, INC. | $22.35 | 2025 | Nanoknife |
| Teleflex LLC | $21.74 | 2025 | Barrigel |
| Verity Pharmaceuticals INC. | $19.10 | 2025 | Tlando |
| Mayne Pharma Commercial LLC | $17.22 | 2021 | |
| Laborie Medical Technologies Corp. | $7.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Butzen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.